Data Bytes: preclinical IPO performance trending up

The last 18 months have seen a trend towards positive aftermarket performance for preclinical IPOs

IPOs by preclinical biotechs since 2013 had largely been hit or miss until the past 18 months, when a trend toward positive aftermarket performance has emerged.

Read the full 265 word article

How to gain access

Continue reading with a
two-week free trial.